Sonelokimab Clears All Phase 3 PsA Hurdles; MoonLake's Cash Runway Extends to Mid-2028
MLTX has more than doubled off its 52-week low of $5.95.
Summary
Sonelokimab hit all endpoints in the Phase 3 IZAR-1 psoriatic arthritis trial, posting a 42.1% ACR50 response with clean safety. MoonLake's $537M cash balance funds operations to mid-2028.
Key Events · Product Development and Regulatory · MLTX
-
Phase 3 IZAR-1 Trial Met All Endpoints
In bio-naïve psoriatic arthritis patients at Week 16, the 60 mg dose of sonelokimab delivered a 42.1% ACR50 response on the primary endpoint, with strong secondary outcomes: ACR20 66.5%, MDA 41.2%, and PASI90 61%.
-
Clean Safety Profile Maintained
A blinded safety analysis revealed no new signals, consistent with prior studies, reinforcing sonelokimab's potential as a leading PsA treatment.
-
Strong Financial Position
Q2 2026 cash and equivalents totaled $537.0M, and up to $400M remains available through a Hercules Capital debt facility, extending the cash runway to mid-2028.
-
Upcoming Catalysts
Key milestones ahead: HS BLA submission expected by end of September 2026; IZAR-2 enrollment completion in Q3 2026; full IZAR-1 readout in H1 2027; and P-OLARIS results late 2026 or early 2027.
Analysis · MLTX · Life Sciences
The Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis met every primary and secondary endpoint, delivering robust efficacy across multiple disease domains. An ACR50 response of 42.1%, combined with high rates of skin clearance (PASI90 61%) and minimal disease activity (MDA 41.2%), positions sonelokimab as a potential best-in-class therapy in a multi-billion dollar market. The safety profile remains clean, with no new signals. With $537 million in cash and a debt facility providing up to $400 million in non-dilutive capital, MoonLake has a clear path to mid-2028—well beyond key catalysts including the HS BLA submission in September 2026 and the IZAR-2 readout. This derisks the PsA program and significantly expands the commercial opportunity beyond hidradenitis suppurativa.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MLTX was trading at $18.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $5.95 to $62.75. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.